PDF-Guidance for Industry New Chemical Entity Exclusivity Determinations for Certai PDF document

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability

Upload by sherrill-nordquist
Published on 2014-10-03

Presentation Embed Code

<iframe width="560" height="315" src="https://www.docslides.com/embed/2451" frameborder="0" allowfullscreen></iframe>

Download Presentation

Download Presentation The PPT/PDF document " Guidance for Industry New Chemical Enti..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Guidance for Industry New Chemical Entity Exclusivity Determinations for Certai: Transcript

PDF-Guidance for Industry New Chemical Entity Exclusivity Determinations for Certai PDF document

Presentation Embed Code

Download Presentation

Guidance for Industry New Chemical Entity Exclusivity Determinations for Certai: Transcript

Related Contents

Subrecipient vs. Contractor Determinations

Guidance for Industry Regulation of Human Cells Tissues and Cellular and TissueBased Products

Procurement Policies under the Uniform Guidance

NFDA Update & Key Initiatives

Making Non-Compliance Determinations

Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance

Guidance for Industry Concerns Related to the use of Clove Oil as an Anesthetic for Fish

Guidance for Industry How to Comply with the Pediatric Research Equity Act DRAFT GUIDANCE

Guidance for Industry Incorporation of Physical Chemical Identifiers into Solid Oral Dosage

Guidance for Industry Applications for Premarket Review of New Tobacco Products DRAFT

Guidance for Industry and FDA Staff Submissions for Postapproval Modifications to a Combination

Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs

Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment

Guidance for Industry ANDA Submissions Prior Approval Supplements Under GDUFA DRAFT GUIDANCE